Aralez Pharmaceuticals unveils new office in Ireland
The Dublin offices are the company's first permanent business premises outside of North America.
Aralez Pharmaceuticals has opened new offices in Dublin, Ireland. The company, which focuses on cardiovascular, pain and other specialty areas, plans to add more highly skilled jobs in Dublin by the end of 2017. Adrian Adams, CEO of Aralez Pharmaceuticals, was joined by Mary Mitchell O'Connor, Minister for Jobs, Enterprise and Innovation, to officiate at the opening ceremony. The Dublin offices are Aralez's first permanent business premises outside of North America.
Speaking at the event, Ms. Mitchell O'Connor said: "The pharma industry makes a huge contribution to the Irish economy in terms of jobs and manufacturing exports, and is one of our fastest growing sectors. In addition to the very big players, we are very keen to attract specialty pharma companies like Aralez who will broaden the reach of the industry here and generate new opportunities. This company's decision to establish its new offices here in Dublin, with quality jobs being created, will help drive the company's expansion into EU markets. I look forward to a mutually beneficial partnership developing."
Mr Adams added: "The opening of our new Ireland headquarters is extremely important to Aralez. Ireland has an excellent reputation as a leading location for talented professionals in the pharmaceutical industry and will be essential to help us grow our operations over the next few years."
Martin Shanahan, CEO of Ireland's Industrial Development Authority said: "Ireland is a globally recognised centre of excellence in life sciences due to the country's strong regulatory track record and talent availability. The pharma industry makes a huge contribution to the Irish economy in terms of the creation of skilled and highly sought after positions. The establishment of Aralez in Dublin represents a welcome endorsement of the talent and business infrastructure which Ireland has to offer. The IDA looks forward to the further growth of Aralez over the course of the next few years."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.